Short Interest in ENDRA Life Sciences Inc. (NASDAQ:NDRA) Declines By 25.3%

ENDRA Life Sciences Inc. (NASDAQ:NDRA) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totaling 58,311 shares, a decline of 25.3% from the December 15th total of 78,064 shares. Based on an average daily volume of 18,189 shares, the short-interest ratio is presently 3.2 days. Currently, 8.6% of the company’s shares are sold short. Currently, 8.6% of the company’s shares are sold short. Based on an average daily volume of 18,189 shares, the short-interest ratio is presently 3.2 days.

ENDRA Life Sciences Price Performance

Shares of ENDRA Life Sciences stock traded up $0.31 during trading on Friday, hitting $4.78. 11,041 shares of the stock were exchanged, compared to its average volume of 14,628. The firm’s 50-day moving average price is $5.32 and its 200 day moving average price is $5.37. The stock has a market cap of $3.59 million, a price-to-earnings ratio of -0.18 and a beta of -0.31. ENDRA Life Sciences has a 12-month low of $2.90 and a 12-month high of $11.96.

ENDRA Life Sciences (NASDAQ:NDRA) last posted its earnings results on Friday, November 14th. The company reported ($1.75) EPS for the quarter, beating the consensus estimate of ($1.95) by $0.20. As a group, research analysts forecast that ENDRA Life Sciences will post -47.46 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Ascendiant Capital Markets cut their target price on ENDRA Life Sciences from $38.00 to $30.00 and set a “buy” rating for the company in a research note on Monday, December 8th. Wall Street Zen upgraded ENDRA Life Sciences to a “sell” rating in a report on Saturday, November 22nd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ENDRA Life Sciences in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $30.00.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.